ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2010-10-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 768
- Registration Number
- NCT00573508
Phase II Study of ASP3550 in Patients With Prostate Cancer
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 273
- Registration Number
- NCT00568516
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 52
- Registration Number
- NCT00567918
Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 56
- Registration Number
- NCT00567762
Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00560326
Long-term Safety of Protopic in Atopic Eczema
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 789
- Registration Number
- NCT00560378
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 323
- Registration Number
- NCT00543569
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Methodist University Hospital - Memphis, Memphis, Tennessee, United States
Distribution of Tacrolimus in Skin, Atopic Dermatitis
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 14
- Registration Number
- NCT00534508
Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 53
- Registration Number
- NCT00535691
ASP8825 - Study in Patients With Restless Legs Syndrome
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 474
- Registration Number
- NCT00530530
© Copyright 2024. All Rights Reserved by MedPath